Compare Johnson & Johnson (JNJ) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Visa Inc — how do they compare? Johnson & Johnson trades at $260.33 (market cap $626.09B), while Visa Inc trades at $359.12 (market cap $671.74B). The key difference: Johnson & Johnson and Visa Inc are close in size by market cap, and Johnson & Johnson pays the higher dividend (2.06%). Which is the better fit depends on your goals.
| JNJ | V | |
|---|---|---|
Market Cap | $626.09B | $671.74B |
Volume | 6,156,228 | 10,431,336 |
Sector | Health | Financials |
52-Week High | $267.24 | $370.47 |
52-Week Low | $172.78 | $295.52 |
Enterprise Value | $654.37B | $682.32B |
Dividend Yield | 2.06% | 0.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.81, up 0.99% on the day and near its 52-week high. The stock exhibits bullish technical signals with strong moving average support, while fundamentals show robust profitability with a net income margin of 21.48% and consistent dividend growth. Recent earnings have mostly beaten expectations, and the company maintains a solid balance sheet with $24.52 billion in cash.
The outlook for JNJ remains positive, supported by analyst consensus and a price target of $284.50. Key opportunities include its defensive healthcare positioning and pipeline strength, though risks involve patent expirations and legal headwinds. The stock offers a stable investment with growth potential in a volatile market.
Visa (V) trades at $361.32, down 0.33% on the day, with a bearish technical signal but strong fundamentals. The stock shows consistent earnings beats, with Q2 2026 EPS of $3.32 exceeding the $3.23 estimate. Revenue grew to $40 billion in 2025, with a net income margin of 50.78%. Recent news highlights Visa's AI initiatives, such as Intelligent Commerce Connect, to enhance payment efficiency.
The outlook remains positive due to high analyst buy ratings (85.48%) and a consensus price target of $426.31, implying 18% upside. Risks include fintech competition and regulatory pressures, but Visa's robust cash flow and profitability support long-term growth potential for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
